scholarly journals Survival benefit of transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: influence of the meld score

HPB ◽  
2017 ◽  
Vol 19 ◽  
pp. S67
Author(s):  
K. Allenson ◽  
N. Bhadkamkar ◽  
R. Zvavanjanja ◽  
A. Baxter ◽  
C. Wray
2014 ◽  
Vol 29 (6) ◽  
pp. 430-436 ◽  
Author(s):  
Yadav Ajit ◽  
Hariprasad Sudarsan ◽  
Gupta Saumya ◽  
Agarwal Abhishek ◽  
Redhu Navneet ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Francesco Fiorica ◽  
Carlo Greco ◽  
Sergio Boccia ◽  
Sergio Sartori ◽  
Antonio Stefanelli ◽  
...  

Introduction. Transarterial chemoembolization is the first-line treatment in unresectable hepatocellular carcinoma. There is no standard treatment after transarterial chemoembolization failure. We report the case of a patient with advanced hepatocellular carcinoma who showed a complete response and a long cancer control with hypofractionated stereotactic radiotherapy after transarterial chemoembolization failure.Case Presentation. A 70-year-old Caucasian woman was treated with transarterial chemoembolization for advanced hepatocellular, but no cancer control was obtained. A hypofractionated stereotactic radiotherapy was planned delivering 40 Gy in 5 fractions. A dramatic reduction in alpha-fetoprotein was observed. Contrast-enhanced ultrasonography at 1 and 2 months showed large necrotic areas. Computerised tomography scan showed a 90% objective tumour response, then a complete remission at 3 and 6 months after treatment, respectively. Status of patient remained unchanged for 2 years.Conclusions. Hypofractionated stereotactic radiotherapy can improve survival and prognosis of unresectable hepatocellular carcinoma patient.


Sign in / Sign up

Export Citation Format

Share Document